A phase I study assessing single and multiple doses of IDX21459 in healthy and HCV-infected subjects

Trial Profile

A phase I study assessing single and multiple doses of IDX21459 in healthy and HCV-infected subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2015

At a glance

  • Drugs IDX 21459 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Idenix Pharmaceuticals
  • Most Recent Events

    • 28 Aug 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top